Details

Autor(en) / Beteiligte

• Landoni, Giovanni
• Lomivorotov, Vladimir V
• Alvaro, Gabriele
• Lobreglio, Rosetta
• Pisano, Antonio
• Guarracino, Fabio
• Calabrò, Maria G
• Grigoryev, Evgeny V
• Likhvantsev, Valery V
• Salgado-Filho, Marcello F
• Bianchi, Alessandro
• Pasyuga, Vadim V
• Baiocchi, Massimo
• Pappalardo, Federico
• Monaco, Fabrizio
• Boboshko, Vladimir A
• Abubakirov, Marat N
• Amantea, Bruno
• Lembo, Rosalba
• Brazzi, Luca
• Verniero, Luigi
• Bertini, Pietro
• Scandroglio, Anna M
• Bove, Tiziana
• Belletti, Alessandro
• Michienzi, Maria G
• Shukevich, Dmitriy L
• Zabelina, Tatiana S
• Bellomo, Rinaldo
• Zangrillo, Alberto

Titel

Levosimendan for Hemodynamic Support after Cardiac Surgery

Ist Teil von

• The New England journal of medicine, 2017-05, Vol.376 (21), p.2021-2031

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• In a randomized trial, 506 patients requiring perioperative hemodynamic support after cardiac surgery were assigned to receive levosimendan or placebo in addition to standard care. There was no significant between-group difference in 30-day mortality. Every year, more than 1 million patients undergo cardiac surgery in the United States and Europe. 1 Acute perioperative left ventricular dysfunction is a major complication affecting up to 20% of such patients 2 , 3 and is associated with increased mortality. 4 Inotropic drugs (catecholamines and phosphodiesterase type 3 [PDE-3] inhibitors) are the cornerstone of postoperative hemodynamic support. 3 , 5 However, no randomized, controlled trials have shown the superiority of any inotropic agent in terms of major clinical outcomes. Furthermore, meta-analyses and observational studies suggest that catecholamines and PDE-3 inhibitors may increase mortality. 6 , 7 Levosimendan (Simdax, Orion) is an inotropic agent that has been . . .